Effect of Intraoperative Blood Transfusion On Treg And Foxp3 In Patients With Digestive Tract Malignancies And Different ABO Blood Types

Yajun Liu  
Affiliated Hospital of Inner Mongolia Medical College

Junzhi Sun  
Affiliated Hospital of Inner Mongolia Medical College

Yun Xia  
Ohio State University Wexner Medical Center

Michael R. Lyaker  
Ohio State University Wexner Medical Center

Jianshe Yu (✉yjsmzk@163.com)  
Affiliated Hospital of Inner Mongolia Medical College

Research article

Keywords: Blood transfusion, ABO blood group, Treg, FOXP3, Immunity, Digestive tract, Malignant tumor

DOI: https://doi.org/10.21203/rs.3.rs-34071/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background Blood transfusion can cause immunosuppression and lead to worse outcomes in patients with digestive tract malignancies; however, the specific mechanism behind this is not completely understood. One theory is that increased numbers of regulatory CD3 + CD4 + CD25 + FOXP3 + T cells (Tregs) and forkhead box protein-3 mRNA (FOXP3) expression in the blood after transfusion contribute to these outcomes. The effect of blood transfusion on immune function in patients with different ABO blood types is variable. This study investigates the effect of intraoperative blood transfusion on the number of Tregs and the expression of FOXP3 in the blood of patients with different ABO blood types and digestive tract malignancies.

Methods Patients with digestive tract malignancies who underwent radical resection and received intraoperative blood transfusion were divided into four groups according to their blood types: blood group A, B, O and AB (n=20). Blood was collected before surgery, immediately after transfusion, 1 day after transfusion, and 5 days after transfusion. The number of Tregs was measured by flow cytometry. The expression of FOXP3 was detected by real time reverse transcription polymerase chain reaction (RT-PCR).

Results There was no significant difference in the number of Tregs or expression of FOXP3 mRNA among patients with different blood types before surgery. However, the number of Tregs and the expression of FOXP3 increased after blood transfusion in all blood type groups. This increase was especially evident and statistically significant on the first day after blood transfusion when compared with measures obtained before the surgery. Measures returned to the preoperative level five days after surgery. There were significant differences in the increase of Tregs and expression of FOXP3 among patients with different blood types. The greatest increase was seen in patients with blood group B and the least in blood group A.

Conclusions Intraoperative blood transfusion can lead to an increase in blood Tregs and FOXP3 expression in patients with digestive tract malignancies. Increases were greatest on the first day after surgery and differed among patients with different blood types. Increases were greatest in blood type B and least in blood type A.

Background

Patients with malignant tumors of the digestive tract often have anemia because of tumor-associated bleeding, malnutrition, bone marrow suppression due to radiotherapy and chemotherapy, and intraoperative blood loss [1-2]. Anemia not only affects the quality of life in these patients, but is also an independent risk factor for death [3]. Perioperative blood transfusion is commonly utilized to improve tissue oxygen delivery and perfusion, but transfusion also carries the risk of adverse effects [4]. Blood transfusion has been shown to cause immunosuppression and can increase the risk of infection and recurrence of malignancy in patients with cancer [5-6]. Such complications can negatively affect a patient's prognosis [2, 7, 8]. Previous studies have found that an increase in regulatory T cells (Tregs) and expression of their specific marker forkhead box protein-3 (FOXP3) after allogenic blood transfusion may be one of the mechanisms of immunosuppression [9]. However, the effect of blood transfusion on Tregs and FOXP3 in patients with digestive tract malignancies is unclear.
Treg generally refers to regulatory CD3<sup>+</sup>CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> T cells. These cells can have immunosuppressive effects through activation and expression of a variety of immune cells by cell-cell contact and cytokine-mediated mechanisms<sup>[10,11]</sup>. FOXP3 is the specific marker of Tregs and is the key to their development, activation, and function<sup>[12,13]</sup>. Deletion of FOXP3 can lead to the loss of Treg suppressive function on autoreactive T cells in scurfy (sf) mice. This has been shown to cause severe autoimmune reactions and death<sup>[14]</sup>. However, since it is an intracellular protein, the FOXP3/scurf protein is not easy to detect. CD127 expression is inversely correlated with FOXP3<sup>[15]</sup>; it is specifically expressed at a low level on the surface of Tregs and can be used as a biomarker for detecting them.

Human ABO blood group substances are abundantly expressed on the surface of red blood cells and in various tissues, organs and body fluids<sup>[16]</sup>. ABO blood groups are associated with various diseases including tumors of the digestive system<sup>[17-21]</sup>. There are also differences in the levels of inflammatory factors and the incidence of transfusion reactions due to erythrocyte concentrates in patients with different ABO blood types<sup>[22]</sup>. The purpose of this study was to investigate the effect of blood transfusion on Tregs and FOXP3 expression in patients with malignant tumors of the digestive tract and different ABO blood types.

**Methods**

This study was approved by the Ethical Committee of the Affiliated Hospital of Inner Mongolia Medical University, and written informed consent was obtained from all patients. The study selected patients at the Affiliated Hospital of Inner Mongolia Medical University from July 2018 to May 2019. Patients were divided into four groups according to their blood types, namely blood group A, blood group B, blood group O and blood group AB. The first 20 patients of each blood type who met selection criteria were assigned to each group. Peripheral venous blood was collected in EDTA anticoagulant tubes before surgery (T<sub>0</sub>), immediately after transfusion (T<sub>1</sub>), 1 day after transfusion (T<sub>2</sub>), and 5 days after transfusion (T<sub>3</sub>). The number of CD3<sup>+</sup>CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> Tregs and the expression of FOXP3 mRNA in the blood were detected.

**Inclusion and Exclusion Criteria**

Inclusion criteria: (1) Patients diagnosed with a malignant tumor of the digestive tract by gastroscopy and needed radical resection (2) Preoperative hemoglobin < 100g/L; (3) Aged 40-65 years old; (4) American Society of Anesthesiologists (ASA) physical status class II or III; (5) Body Mass Index (BMI) 18.5-24.9kg/m<sup>2</sup>; (6) Rh blood group positive.

Exclusion criteria: (1) Severe lung or heart disease; (2) Presence of immune disease or recent use of immunosuppressive agents; (3) White blood cell count < 2 × 10<sup>9</sup>/L or platelet count < 80 × 10<sup>9</sup>/L; (4) prothrombin time more than 3s longer than normal control or activated partial thromboplastin time more than 10s longer than normal control; (5) Patients with a history of blood transfusion before surgery; no intraoperative blood transfusion was given; massive transfusion (transfusion of more than 4 units red
blood cells within 1 h or 50% of total blood volume within 3 h) required during surgery or postoperative blood transfusion given.

**Anesthetic Technique**

All patients were treated with combined epidural and general anesthesia technique. A radial artery catheter and a central venous catheter were placed before induction of anesthesia. The epidural insertion level was selected according to the surgical site, and the catheter was introduced through an 18-gauge needle in the corresponding intervertebral space. Epidural administration: A test dose of 3-5 ml of 1.5-2% lidocaine (with epinephrine) was given. The loading dose was 10 ml of 0.25-0.5% ropivacaine and supplemented with 5 mL of 0.25-0.5% ropivacaine every 40 min. General anesthesia was induced with sufentanil 0.4 µg/kg, etomidate 0.3 mg/kg, and rocuronium bromide 0.6mg/kg. General anesthesia was maintained by a continuous intravenous infusion of propofol and remifentanil. Propofol infusion during general anesthesia (GA) was adjusted to maintain the bispectral index between 40-60. Remifentanil was administered according to blood pressure changes. Paralysis was maintained with 0.2 mg/kg rocuronium bromide dosed every 40 minutes. Mechanical ventilation was adjusted to maintain end-tidal carbon dioxide tension ($P_{ET}CO_2$) of 35-45 mmHg. At the end of surgery 3 mg of ramosetron was administered. Postoperative analgesia was performed with patient-controlled epidural analgesia (PCEA) (sufentanil 30ug, ropivacaine 375 mg in 250 ml of normal saline). The PCEA was maintained for 48 hours using an infusion rate of 5 mL/h, a 3 mL demand bolus and a lock-out interval of 15 min.

**Blood Transfusion Method**

All patients had a preoperative type and cross performed. According to the ASA "Practice Guidelines for Perioperative Blood Management" [23] and Chinese "Technical Specifications for Clinical Transfusion" [24], transfusion is not indicated when the hemoglobin concentration is above 10 g/dL, is indicated when the hemoglobin concentration is less than 7 g/dL, and should be guided by symptoms for patients with hemoglobin concentrations between 7 and 10 g/dL. The anesthesiologist determined the amount of blood transfused based on a comprehensive evaluation of the patient's anemia, blood volume, blood loss, severity of shock, cardiopulmonary status and hemodynamic indicators.

**CD3⁺CD4⁺CD25⁺CD127^[low] Treg Detection**

50 µL of anticoagulated whole blood was thoroughly mixed in a test tube with 10 µL each of CD4-FITC/FL1-A (BD340133), CD25-APC/FL4-H (BD340938), CD127-PE/FL2-H (BD561028) monoclonal antibodies. The mixture was protected from light and maintained at room temperature for 15 minutes. Subsequently, 2 mL of a 1: 10 diluted FACS Lysing solution was added. The tube was incubated for 10 more minutes at room temperature while protected from light during lysis. The tube was centrifuged at 1500 rpm for 5 minutes and the supernatant removed. After adding 2mL of phosphate buffer solution (PBS), the tube was again centrifuged at 1500 rpm for 5 minutes. The supernatant was removed and 500 µL PBS was added for detection. Detection was performed using a BD FACSCanto II flow cytometer, and
analyzed by BD FACSDiva software to obtain the percentage of CD3⁺CD4⁺CD25⁺CD127low Treg in CD4⁺T cells.

**FOXP3 mRNA Detection**

RNA was extracted using Trizol. The optical density (OD)260/OD280 ratios were measured with a microspectrophotometer to assess the RNA quality. A ratio between 1.8 and 2.0 met the experimental requirements. The total RNA concentration (µg/µL) = OD260 × 40 × 10⁻³. First strand cDNA synthesis was performed using 10µM oligo(dT)18 primer and Hiscript reverse transcriptase. Reaction conditions were 5 minutes at 25°C, 15 minutes at 50°C, 5 minutes at 85°C, and 10 minutes at 4°C. The resulting cDNA was diluted twice before proceeding with the PCR reaction. The relative DNA amount of FOXP3 mRNA was determined using SYBR Green Master Mix, and the internal reference gene GAPDH was measured in each sample. The PCR reaction conditions were 40 cycles at 50°C for 2 minutes, 95°C for 10 minutes, 95°C for 30 seconds, and 60°C for 30 seconds. The primer sequences are as follows: FOXP3 upstream primer 5’-CATTCCCAGAGTTCCTCCACA-3’, downstream primer 5’-CATTGAGTGTCGCTGCTTC-3’; the internal reference gene GAPDH upstream primer 5’-TCAAGAAGGTGGTGAGACAGG-3’, and downstream primer 5’-TCAAAGGTGGAGGTGGGT-3’. Triplicate wells were conducted for each specimen, and the final data was analyzed for changes in the relative expression level of FOXP3 mRNA using the 2⁻ΔΔCt method [25, 26].

**Statistical Analysis**

The data were analyzed by using SPSS 18.0. Quantitative data were expressed as mean ± standard deviation ( ¯x ± s), and discrete data were expressed as numbers. Comparison within groups at different time points was performed by repeated measures Analysis of Variance (ANOVA), and comparison between different groups at the same time points was performed using the Bonferroni test. Discrete data were compared using chi-square test or Fisher's exact test. P < 0.05 was considered as statistically significant.

**Sample Size**

\[ n = \left[ \frac{Z_{\alpha/2} + Z_{\beta}}{1n(\frac{1+p}{1-p})} \right]^2 + 3 \]

The formula was used to estimate sample size based on the correlation coefficient test. The correlation coefficient of 0.7 was substituted into the formula; assuming two-sided \( \alpha = 0.05, \beta = 0.10 \), then the sample size would be \( n \approx 17 \). Therefore at least 17 cases were required for each group.

**Results**

**Patient Demographics**
There were no significant differences among different blood groups with regard to age, gender, BMI, tumor type, treatment history, preoperative hemoglobin, operative time, operative technique or volume of intraoperative blood transfusion (P > 0.05). (Table 1).

**Flow cytometry assay comparison of CD3\(^+\)CD4\(^+\)CD25\(^+\)CD127\(^{low}\)Tregs at different time points for different blood types**

Between-group and within-group ANOVA was performed on CD3\(^+\)CD4\(^+\)CD25\(^+\)CD127\(^{low}\) Tregs in the four groups of patients with different blood types (Table 2) (Figure 1). The results showed that there was no significant difference in peripheral blood CD3\(^+\)CD4\(^+\)CD25\(^+\)CD127\(^{low}\) Treg numbers among patients with different blood types at T\(_0\) (P > 0.05). The number of Tregs increased at T\(_1\), but there was no statistically significant difference from T\(_0\) (P > 0.05). At T\(_2\) Treg numbers were significantly increased compared with T\(_0\) (P < 0.05). At T\(_3\) Treg numbers returned to preoperative levels, and there was no significant difference compared with T\(_0\) (P > 0.05). The degree of increase in CD3\(^+\)CD4\(^+\)CD25\(^+\)CD127\(^{low}\) Treg numbers after blood transfusion was different among patients with the four different blood types. The highest increase was seen in blood group B and the least in blood group A; This difference was statistically significant (P < 0.05) at T\(_2\). The results of CD3\(^+\)CD4\(^+\)CD25\(^+\)CD127\(^{low}\) Treg detection by flow cytometry are shown in Figure 2.

**Comparison of FOXP3mRNA at different time points in different blood types**

The FOXP3mRNA expression at T\(_1\), T\(_2\) and T\(_3\) relative to T\(_0\) in all patients was calculated by relative quantitative calculation using \(2^{-\Delta\Delta C_t}\) formula; the fold-change of absolute expression > 2 was considered to be statistically significant. The FOXP3mRNA expression at T\(_0\) among all patients with different blood types was 1. Between-group and within-group ANOVA was performed on FOXP3mRNA in the four groups of patients with different blood types (Table 3) (Figure 3). Results showed that compared with T\(_0\), expression of FOXP3mRNA in the peripheral blood of patients with all four blood types began to increase at T\(_1\) (fold-change < 2), peaked at T\(_2\) (fold-change > 2) and then decreased to preoperative levels at T\(_3\) (fold-change < 2). The degree of increase in FOXP3mRNA expression was different after blood transfusion among patients within the four blood types. The highest increase was seen in blood group B and the lowest was seen in blood group A. This difference was statistically significant (P < 0.05).

**Discussion**

The immune system plays a key role in the body's defense against malignancy. While immune function in patients with malignant tumors is often impaired, the specific mechanism is not clear. Numerous studies have demonstrated that Tregs and FOXP3 are increased in the peripheral blood and tumors of patients with digestive tract malignancies and are positively correlated with tumor stage\(^{[27, 28]}\). In addition, increases of Tregs and FOXP3 in patients with digestive tract malignancies are associated with a poor prognosis because of an association with tumor immune escape\(^{[29]}\). Tregs are mainly produced by the
thymus (tTregs), but can also be produced in the periphery (pTregs) or induced in cell culture (iTregs) [30]. Tregs can directly or indirectly inhibit the activation of natural killer (NK) cells, cytotoxic T lymphocytes, monocytes, B cells, inhibit the expression of macrophages, and regulate the expression of T helper type 1 (Th1) and type 2 (Th2) cells. This occurs through direct cell-to-cell contact [10], secretion of multiple inhibitory cytokines such as transforming growth factor-β (TGF-β), interleukin (IL)-10, and through inhibiting the production of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) [15]. These actions cumulatively exert an immunosuppressive effect on the body’s defenses [11]. FOXP3 is a member of the forkhead/winged-helix transcription factor family. It is specifically expressed on Treg without being affected by activation status and is distinct from other molecular markers of Tregs such as CD25, CD45RB, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and glucocorticoid-induced tumor necrosis factor receptor (GITR). FOXP3 is the key to the development, activation and function of Tregs [12, 13]. FOXP3 may also participate in the regulation of Tregs through the dual roles of transcription repressor and activator [10]. Only changes in FOXP3 on thymus Tregs can affect Treg numbers in peripheral blood [31].

Patients with digestive tract malignancies often have pre-existing anemia and require intraoperative blood transfusion [2]. Blood transfusion can increase the risk of metastasis and recurrence, as well as the incidence of complications such as local infection, pneumonia, and sepsis [5, 6]. Factors such as autologous and allogeneic blood transfusion [32, 33], use of different blood products and blood storage times [34], have been commonly studied with regard to immunosuppression. However, the mechanism of immunosuppression from blood transfusion remains uncertain [9, 35]. Proposed mechanisms include: enhanced secretion of cytokines such as prostaglandins, thromboxane, growth factors, nonpolar lipids and pro-inflammatory lysophosphatidylcholines [36-38]; down-regulated expression of Th1 type cytokines (IL-2, IL-12, IFN-γ and TNF-γ); up-regulated expression of Th2 type cytokines (IL-4, IL-5, IL-6 and IL-10) [37]; increases in the population of Tregs [38] and formation of microparticles [39] among others. At present, few studies have explored the mechanism of blood transfusion induced immunosuppression in patients with digestive tract malignancies. Transfusion-induced up-regulation of Tregs and FOXP3 may be an important mechanisms of immunosuppression after blood transfusion in patients with digestive tract malignancies [9]. The present study shows that intraoperative blood transfusion may temporarily increase the number of Tregs and the expression of FOXP3 in this patient population. This was especially evident on postoperative day 1 and resolved by postoperative day 5. Given the known role of Tregs in modulating immune function, our finding supports that increased blood levels of Treg and FOXP3 may play an important role in the immunosuppression seen with blood transfusion. Since, the observation time of this study was short and the sample size was relatively small, these results still need further investigation to confirm.

The ABO blood group antigen system was discovered a century ago. Human ABO blood group system consists of three alleles (A, B, O) and four phenotypes. Studies have shown that ABO blood groups are associated with various diseases such as cardiovascular disease [20], diabetes [21], and malignant tumors
including those of the digestive tract\textsuperscript{[17-19]}. The incidence of transfusion reactions and levels of inflammatory cytokines also differs among patients with different ABO blood groups.\textsuperscript{[22]} However, the biological and functional role of the ABO blood group antigen system remains a mystery\textsuperscript{[40]}. This study showed that the degree of increase in Tregs and FOXP3 after blood transfusion was different in patients with different ABO blood types. This increase was highest among patients with blood type B and least in patients with blood type A. This finding suggests that the degree of immunosuppression in patients with digestive tract malignancies and different ABO blood types may also vary. Further studies with larger numbers of patients are still needed to confirm this finding. We speculate that the increase in the number of Tregs and FOXP3 expression in these patients may be related to the lack of the A antigen on erythrocytes or the increase of anti A antibodies in the plasma; however, the exact mechanism requires further investigation. The correlation between different ABO blood types and immunosuppression after blood transfusion has significant implications in clinical blood use. For example, patients with blood type B and a high risk of requiring perioperative transfusion may benefit from a comprehensive, individualized blood management protocol to reduce the need for blood transfusion as much as possible.

In conclusion, our results found that intraoperative blood transfusion may lead to an increase in Treg and FOXP3 in the blood of patients with digestive tract malignancies. The degree of increase was different among patients with different ABO blood types. Blood type B had the highest increase and blood type A showed the lowest increase. These findings suggest that the degree of immunosuppression after blood transfusion in patients with digestive tract malignancies and different ABO blood types might be different as well. While these findings still need to be confirmed by larger trials, such investigations may lead to individualized blood management for patients with different ABO blood types.

**Abbreviations**

**Tregs**: Regulatory CD3+CD4+CD25+FOXP3+ T cells;

**FOXP3**: Forkhead box protein-3

**RT-PCR**: Real time reverse transcription polymerase chain reaction;

**ASA**: American Society of Anesthesiologists;

**BMI**: Body Mass Index;

**GA**: General anesthesia;

**P_{ET}CO_2**: End-tidal carbon dioxide tension;

**PCEA**: Patient-controlled epidural analgesia;

**PBS**: Phosphate buffer solution;
Acknowledgments

We acknowledge Ruixia Liu, Inner Mongolia Yuwei Medical Devices Co, Ltd, hohhot, Inner Mongolia, China, for flow cytometry detection.

Authors' contributions

JSY initiated the study, participated in its design and coordination, performed the statistical analysis. YJL carried out the study, and drafted the manuscript. JZS helped to carried out the study and drafted the manuscript. YX helped conduct the study, analyze the data and prepare the manuscript. MRL helped analyze the data, write and edit the manuscript. All authors read and approved the final manuscript.

Funding

None

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Ethical Committee of the Affiliated Hospital of Inner Mongolia Medical University, and written informed consent was obtained from all patients.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Authors’ Affiliations

1) Department of Anesthesiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China

2) Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210, U.S.A.

References

[1] Calleja JL, Delgado S, del Val A, Hervás A, Larraona JL, Terán Á, et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia[J]. International Journal of Colorectal Disease, 2016, 31(3):543-551.

[2] Dongze Hou, Jinsong Dai, Zhibo Deng, Denggao Yan. Effects of hemoglobin level and perioperative blood transfusion on prognosis of patients with colon cancer[J]. Modern Oncology, 2018, 26(07):1070-1074.

[3] Ceanga AI, Ceanga M, Eveslage M, Hermann E, Fischer D, Haferkamp A, et al. Preoperative anemia and extensive transfusion during stay-in-hospital are critical for patient’s mortality: A retrospective multicenter cohort study of oncological patients undergoing radical cystectomy[J]. Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis, 2018, 57(6):739-745.

[4] Ness PM, Triulzi DJ, Carson JL. Adverse Effects of Red-Cell Transfusion[J]. New England Journal of Medicine, 2018, 378(1):97.

[5] Aquina CT, Blumberg N, Becerra AZ, Boscoe FP, Schymura MJ, Noyes K, et al. Association Among Blood Transfusion, Sepsis, and Decreased Long-term Survival After Colon Cancer Resection[J]. Annals of Surgery, 2017, 266(2):311-317.

[6] Hart S, Cserti-Gazdewich CM, McCluskey SA. Red cell transfusion and the immune system[J]. Anaesthesia, 2015, 70(s1):38-45.
[7] Xiaowen Liu, Mingze Ma, Hua Huang, Yanong Wang. Effect of perioperative blood transfusion on prognosis of patients with gastric cancer: a retrospective analysis of a single center database[J]. BMC Cancer, 2018, 18(1):649.

[8] Qianyun Pang, Ran An, Hongliang Liu. Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis[J]. World Journal of Surgical Oncology, 2019, 17(1):7.

[9] Cata JP, Wang H, Gottumukkala V, Reuben J, Sessler DI. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions[J]. British Journal of Anaesthesia, 2013, 110(5):690-701.

[10] Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression[J]. Immunity, 2009, 30(5):636-645.

[11] Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis[J]. Frontiers in Immunology, 2017, 8:605.

[12] Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: Forkhead box protein 3 mutations and lack of regulatory T cells[J]. Journal of Allergy and Clinical Immunology, 2007, 120(4):744-750.

[13] Jinhui Tao, Miao Cheng, Jianguo Tang, Qin Liu, Fan Pan, Xiangpei Li. Foxp3, Regulatory T Cell, and Autoimmune Diseases[J]. Inflammation, 2017, 40(1):328-339.

[14] Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells[J]. Nature Immunology, 2003, 4(4):330-336.

[15] Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells[J]. Journal of Experimental Medicine, 2006, 203(7):1701-1711.

[16] Watkins WM. The ABO blood group system: historical background[J]. Transfusion Medicine, 2010, 11(4):243-265.

[17] Zhiwei Wang, Lei Liu, Jun Ji, Jianian Zhang, Min Yan, Jun Zhang, et al. ABO Blood Group System and Gastric Cancer: A Case-Control Study and Meta-Analysis[J]. International Journal of Molecular Sciences, 2012, 13(10):13308-13321.

[18] Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB. ABO blood group and cancer[J]. European Journal of Cancer, 2010, 46(18):3345-3350.

[19] Bailin Zhang, Na He, Yubei Huang, Fengju Song, Kexin Chen. ABO Blood Groups and Risk of Cancer: a Systematic Review and Meta-analysis[J]. Asian Pacific journal of cancer prevention: APJCP, 2014,
[20] Franchini M, Lippi G. The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer[J]. BMC Medicine, 2015, 13(1):7.

[21] Fagherazzi G, Gusto G, Clavel-Chapelon F, Balkau B, Bonnet F. ABO and Rhesus blood groups and risk of type 2 diabetes: evidence from the large E3N cohort study[J]. Diabetologia, 2015, 58(3):519-522.

[22] Jianshe Yu, Yaying Xie, Yiri Du, Haixia Shi, Dongmei Chen, Zhiqiang Han. Effects of ABO blood group factors on erythrocyte suspension transfusion reactions[J]. Chinese Journal of Anesthesiology, 2015, (12):1425-1427.

[23] Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*[J]. Anesthesiology, 2015, 122(2):241-275.

[24] Technical specifications for clinical blood transfusion [J]. Chinese Hospital, 2000, 4 (6):1-11.

[25] Yuan JS, Reed A, Chen F, Stewart CN Jr. Statistical analysis of real-time PCR data[J]. BMC Bioinformatics, 2006, 7(1):85.

[26] Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method[J]. Methods, 2001, 25(4):402-408.

[27] Yiting Geng, Hui Wang, Changqing Lu, Qing Li, Bin Xu, Jingting Jiang, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+Tregs in gastric cancer and its clinical significance[J]. International Journal of Clinical Oncology, 2015, 20(2):273-281.

[28] Ganapathi SK, Beggs AD, Hodgson SV, Kumar D. Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance[J]. British Journal of Cancer, 2014, 111(8):1581-1589.

[29] Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM. Treg(s) in Cancer: Friends or Foe?[J]. Journal of Cellular Physiology, 2015, 230(11):2598-2605.

[30] Shevach EM, Thorn ton AM. tTregs, pTregs, and iTregs: similarities and differences[J]. Immunological Reviews, 2014, 259(1):88-102.

[31] Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor foxp3[J]. Journal of Experimental Medicine, 2003, 198(12):1875-1886.

[32] Bower MR, Ellis SF, Scoggins CR, McMasters KM, Martin RC. Phase II comparison study of intraoperative autotransfusion for major oncologic procedures[J]. Annals of Surgical Oncology, 2011,
[33] Amico F, Briggs G, Balogh ZJ. Transfused trauma patients have better outcomes when transfused with blood components from young donors[J]. Medical hypotheses, 2019, 122:141-146.

[34] Mouw TJ, Lu J, Woody-Fowler M, Ashcraft J, Valentino J, DiPasco P, et al. Morbidity and mortality of synchronous hepatectomy with cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)[J]. Journal of Gastrointestinal Oncology, 2018, 9(5):828-832.

[35] Landers DF, Hill GE, Wong KC, Fox IJ. Blood Transfusion-Induced Immunomodulation[J]. Anesthesia and Analgesia, 1996, 82(1):187-204.

[36] Youssef LA, Spitalnik SL. Transfusion-related immunomodulation: a reappraisal.[J]. Current Opinion in Hematology, 2017, 24(6):551-557.

[37] Sahu S, Hemlata H, Verma A. Adverse events related to blood transfusion[J]. Indian Journal of Anaesthesia, 2014, 58(5):543-551.

[38] Cata JP, Gottumukkala V. Blood transfusion practices in cancer surgery[J]. Indian Journal of Anaesthesia, 2014, 58(5):637-642.

[39] Danesh A, Inglis HC, Jackman RP, Wu S, Deng X, Muench MO, et al. Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro[J]. Blood, 2013, 123(5):687-696.

[40] Greenwell P. Blood group antigens: molecules seeking a function?[J]. Glycoconjugate Journal, 1997, 14(2):159-173.

Figures
Figure 1

Comparison of CD3+CD4+CD25+CD127low Tregs at different time points in different blood types. A, blood group A; B, blood group B; O, blood group O; AB, blood group AB. T0, before surgery; T1, immediately after transfusion; T2, 1 day after transfusion; T3, 5 days after transfusion. Compared with T0, □P < 0.05; compared with blood group B, O, AB, ▲P < 0.05; compared with blood group A, O, AB, △P < 0.05.
Figure 2

Flow cytometry image. Flow cytometric gating scheme for Treg: Starting from lymphocytes by FSC and SSC gating, cells were further gated on CD4+ and CD25+, then CD127low was used to define Treg population as CD4+CD25+CD127low T lymphocytes, gating of this marker was based on CD4+ T lymphocytes.

Figure 3

Comparison of FOXP3mRNA at different time points in different blood types. A, blood group A; B, blood group B; O, blood group O; AB, blood group AB. T0, before surgery; T1, immediately after transfusion; T2, 1 day after transfusion; T3, 5 days after transfusion. Compared with T0, ▲ fold-change > 2; compared with blood group B, O, AB, △ P < 0.05; compared with blood group A, O, AB, ΔP < 0.05.